Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Evotec SE, a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in Hamburg, Germany. Founded in 1993, the company has established itself as a key innovator in drug discovery and development, with a strong presence across Europe and North America.
Specialising in integrated drug development solutions, Evotec offers a unique platform that combines cutting-edge technologies with extensive expertise in various therapeutic areas. The company is renowned for its collaborative approach, partnering with biopharmaceutical firms to accelerate the development of novel therapies.
With a robust portfolio of services, including target identification, preclinical development, and clinical trial support, Evotec has positioned itself as a trusted partner in the pharmaceutical landscape. Its commitment to scientific excellence and operational efficiency has garnered recognition, making it a prominent force in the global market.
+55 vs industry average
Evotec’s score of 97 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Evotec, headquartered in Germany and operating in Pharmaceutical Preparation Manufacturing, has committed to ambitious climate action.
The company's latest reported total emissions for 2025 are approximately 139,870,000 kg CO2e. This includes:
For 2024, Evotec reported total emissions of approximately 200,930,000 kg CO2e, comprising:
In 2023, the company's total emissions were approximately 300,670,000 kg CO2e, broken down into:
Evotec has set Science Based Targets initiative (SBTi) approved goals:
Evotec's emissions data and climate commitments are directly reported by Evotec SE.
2032
50.4% reduction in Scope 1
Evotec SE commits to reduce absolute scope 1 GHG emissions 50.4% by 2032 from a 2021 base year.
2032
50.4% reduction in Scope 2
Evotec SE commits to reduce absolute scope 2 GHG emissions 50.4% by 2032 from a 2021 base year.
2045
Evotec SE commits to reach net-zero greenhouse gas emissions…
Evotec SE commits to reach net-zero greenhouse gas emissions across the value chain by 2045.
See all 4 climate goals
Already have an account? Sign in now
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Evotec’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more